HTB

American Association For The Study of Liver Diseases (AASLD), November 11-15, 2005 San Francisco

13 December 2005. Related: On the web.

A wide range of reports form the AASLD conference are online on the NATAP.org website:

National AIDS Treatment Advocacy Project – NATAP
http://www.natap.org

American Association for the Study of Liver Diseases November 11-15, 2005 San Francisco
http://www.natap.org/2005/AASLD/aasld.htm

Reports include studies of new treatments, transplantation and monitoring fibrosis in liver disease:

  • Consensus Interferon: study results at AASLD
  • Albuferon-Alpha (Albumin-Interferon Alpha) (11/17/05)
  • REPEAT Study: Non-responders to =12 weeks’ treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11/15/05)
  • Albuferon + ribavirin in PegIFN non-responders: phase 2 study (11/15/05)
  • SCH 503034 HCV protease inhibitor monotherapy in HCV genotype 1 IFN non-responders (11/15/05)
  • VX-950 hepatitis C Protease inhibitor (11/15/05)
  • Combination therapy with SCH-503034 HCV protease inhibitor & PegIntron in non-responders: phase 1b study results (11/15/05)
  • Performance of APRI for the diagnosis of significant hepatic fibrosis is improved by a simple modification (11/14/05)
  • Long term results after therapy with pegylated interferon alpha-2a (Pegysys) in HCV-positive liver transplant recipients.
  • Predicting outcome in patients with HCV after organ liver transplant: a 15-year follow-up. (11/14/05)
  • Recurrent hepatitis C is a risk factor for poor outcome after liver retransplantation. (11/14/05)
  • Multicentred randomised trial of HCV treatment with PegInterferon-alpha 2a (Pegasys) and ribavirin after liver transplantation: one year report (11/14/05)
  • On treatment virological response of 70% in 100 patients treated with combination antiviral therapy for recurrent HCV following liver transplantation. (11/14/05)
  • Is liver biopsy justified in hepatitis C genotype 2 and 3? (11/14/05)
  • Fibroscan, monitoring liver stiffness: a new tool to measure liver fibrosis during therapy. (11/14/05)
  • Telbivudine (LdT) Phase 3 One Year Study Results (11/14/05)
  • Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11/14/05)
  • Virological and histological features of HCV in patients with normal ALT: results of a ten year prospective follow-up study. (11/14/05)
  • African-American patients had fewer office visits and were less likely to return for a second office visit (11/14/05)
  • Coffee drinking decreases the risk of chronic liver disease in the US population. (11/14/05)
  • Impact of caffeine consumption on ALT and histological activity in patients with chronic active HCV. (11/14/05)
  • Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11/14/05)
  • Study evaluations of non-invasive fibrosis tests (11/14/05)
  • Liver histology in hepatitis C patients with normal ALT levels. (11/14/05)
  • Hispanics developed cirrhosis more quickly due to the presence of fatty liver & diabetes (11/14/05)
  • Cannabinoids block interferon-mediated suppression of hepatitis C virus (HCV) replication. (11/14/05)
  • Cryoblobinemia is associated with steatosis and fibrosis in chronic HCV. (11/14/05)
  • Independent validation and comparison with fibroscan, fibrotest and liver biopsy of clinical glycomics for the non invasive assessment of liver fibrosis in chronic HCV. (11/14/05)
  • New hepatitis C polymerase inhibitor HCV-796 study in patients – (11/11/05)

Links to other websites are current at date of posting but not maintained.